Trials / Completed
CompletedNCT01167309
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients
LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety and tolerability of ascending single and multiple oral doses of LEO 27847 in secondary hyperparathyroidism patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 27847 | First in patient |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-12-01
- First posted
- 2010-07-22
- Last updated
- 2025-02-24
Locations
2 sites across 2 countries: Germany, Poland
Source: ClinicalTrials.gov record NCT01167309. Inclusion in this directory is not an endorsement.